newsfilter
← Latest News
PR Newswire·

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

  • POMDOCTOR LIMITED received a Nasdaq Compliance Letter on November 5, 2026, confirming it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 54ade 5450(a)(1).
  • The Nasdaq Hearings Panel hearing originally scheduled for November 12, 2026, has been cancelled as a result of this compliance confirmation.
  • The delisting determination letter previously issued by Nasdaq staff on October 6, 2026, was due to the Company's closing bid price remaining below $1.00 per share for 30 consecutive business days.
  • POMDOCTOR's Class A ordinary shares will continue to be listed & traded on Nasdaq under the ticker symbol "POM".
  • POMDOCTOR LIMITED operates as a digital healthcare company focused on advancing AI-enabled healthcare solutions & predictive healthcare capabilities using physician resources, wearables, & real-world data.
  • Forward-looking statements in the announcement involve known & unknown risks, with the Company undertaking no obligation to update such statements except as required by law.
  • Investor inquiries can be directed to the Company's Investor Relations Department or Ascent Investor Relations LLC via the provided contact information.
Company
POMDOCTOR LIMITED
Keywords
POMDOCTOR LIMITED